CA2864797C - Methods of treating amyotrophic lateral sclerosis - Google Patents

Methods of treating amyotrophic lateral sclerosis Download PDF

Info

Publication number
CA2864797C
CA2864797C CA2864797A CA2864797A CA2864797C CA 2864797 C CA2864797 C CA 2864797C CA 2864797 A CA2864797 A CA 2864797A CA 2864797 A CA2864797 A CA 2864797A CA 2864797 C CA2864797 C CA 2864797C
Authority
CA
Canada
Prior art keywords
compound
als
administration
oxidative stress
stress associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2864797A
Other languages
English (en)
French (fr)
Other versions
CA2864797A1 (en
Inventor
Per Gjorstrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANIDA PHARMA Inc
Original Assignee
ANIDA PHARMA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ANIDA PHARMA Inc filed Critical ANIDA PHARMA Inc
Publication of CA2864797A1 publication Critical patent/CA2864797A1/en
Application granted granted Critical
Publication of CA2864797C publication Critical patent/CA2864797C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2864797A 2012-02-15 2013-02-15 Methods of treating amyotrophic lateral sclerosis Active CA2864797C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261599096P 2012-02-15 2012-02-15
US61/599,096 2012-02-15
PCT/US2013/026284 WO2013123290A1 (en) 2012-02-15 2013-02-15 Methods of treating amyotrophic lateral sclerosis

Publications (2)

Publication Number Publication Date
CA2864797A1 CA2864797A1 (en) 2013-08-22
CA2864797C true CA2864797C (en) 2022-03-22

Family

ID=48984729

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2864797A Active CA2864797C (en) 2012-02-15 2013-02-15 Methods of treating amyotrophic lateral sclerosis

Country Status (5)

Country Link
US (1) US9340483B2 (https=)
EP (1) EP2814479B1 (https=)
JP (1) JP6173352B2 (https=)
CA (1) CA2864797C (https=)
WO (1) WO2013123290A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7689356B2 (ja) * 2017-01-18 2025-06-06 ウニヴェルジテート オートノマ デ バルセロナ 神経変性疾患及び／又は自己免疫性疾患の処置において使用するための抗炎症性脂質メディエーター
US11583511B2 (en) 2017-07-20 2023-02-21 Universitat Autonoma De Barcelona Maresins for use in the treatment of CNS injuries
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
US20250381161A1 (en) * 2022-06-21 2025-12-18 Anida Pharma Inc. Compositions and methods for treating hearing and ocular disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4932116B2 (ja) 2000-02-16 2012-05-16 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アスピリン誘発脂質メディエータ
US7030126B2 (en) * 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004093802A2 (en) 2003-04-17 2004-11-04 The Board Of Trustees Of The Leland Stanford Junior University Prevention of deficits in neurogenesis with anti-inflammatory agents
EP1660069A4 (en) * 2003-08-05 2009-03-18 Univ Louisiana State NEUROPROTECTION AGAINST CELL APOPTOSIS, NEURAL STROKES, ALZHEIMER DISEASE AND RETINAL DEGENERATION
SI1691814T1 (sl) * 2003-12-01 2012-11-30 Cambridge Entpr Ltd Protivnetna zdravila
US8273792B2 (en) * 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
EP2120920A4 (en) * 2007-02-20 2011-06-15 Martek Biosciences Corp OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE
CA2723139A1 (en) * 2007-07-30 2009-02-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells
GB2452696B (en) * 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
CA2699483A1 (en) 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Compositions and methods for modulating immune function
EP2217558A1 (en) 2007-10-31 2010-08-18 Pronova Biopharma Norge AS New dha derivatives and their use as medicaments
US7782152B2 (en) 2008-08-14 2010-08-24 Broadcom Corporation Monotonic frequency tuning technique for DCXO in cellular applications
US20120122816A1 (en) 2009-02-05 2012-05-17 Resolvyx Pharmaceuticals, Inc. Compositions and methods for organ preservation
USRE48077E1 (en) * 2013-02-28 2020-07-07 Anida Pharma Inc. Methods of treating ototoxicity

Also Published As

Publication number Publication date
EP2814479A4 (en) 2015-07-01
CA2864797A1 (en) 2013-08-22
WO2013123290A1 (en) 2013-08-22
WO2013123290A9 (en) 2014-09-12
US9340483B2 (en) 2016-05-17
EP2814479A1 (en) 2014-12-24
US20150010549A1 (en) 2015-01-08
JP6173352B2 (ja) 2017-08-02
JP2015510517A (ja) 2015-04-09
EP2814479B1 (en) 2019-09-04

Similar Documents

Publication Publication Date Title
US20240180919A1 (en) Ezh2 inhibitors for treating cancer
US11591353B2 (en) Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
US20240139203A1 (en) Use of ezh2 inhibitors for treating cancer
WO2019147783A1 (en) Sulfonamide derivatives for protein degradation
WO2018183923A1 (en) Methods of using ehmt2 inhibitors
AU2020358970B2 (en) Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases
CA2864797C (en) Methods of treating amyotrophic lateral sclerosis
TWI886093B (zh) D-絲胺酸之氘化類似物及其用途
JP2024515062A (ja) 重水素化ｄｈｏｄｈ阻害剤
WO2021027744A1 (zh) 3-羟基-5-孕烷-20-酮衍生物及其用途
ES2381180T3 (es) Utilización de derivados de indol como activadores de nurr-1, para el tratamiento de la enfermedad de parkinson
JP2024546138A (ja) トリプタミンプロドラッグ
US9987244B2 (en) Methods of treating ototoxicity
CN114728920B (zh) 一种沃替西汀前药及其应用
US20100273787A1 (en) Kynurenine-aminotransferase inhibitors
KR20160146689A (ko) 파킨슨병을 치료하기 위한 도파민 효능제 및 l-dopa 유도체를 포함하는 조성물
IL317344A (en) Substances and their use for the treatment of mental or neurological diseases
CN104822647B (zh) 四氢异葎草酮的衍生物，制造和使用方法
WO2022022472A1 (zh) 烟酰胺核苷芳甲酸酯类化合物及其组合物的用途以及化合物晶型

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180215

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260312

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260313

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260330